Baillie Gifford & Co’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-806,097
| Closed | -$23.1M | – | 289 |
|
|
2024
Q2 | $23.1M | Sell |
806,097
-194,677
| -19% | -$5.54M | 0.02% | 172 |
|
|
2024
Q1 | $29.2M | Sell |
1,000,774
-62,492
| -6% | -$1.92M | 0.02% | 173 |
|
|
2023
Q4 | $35.9M | Sell |
1,063,266
-573,810
| -35% | -$16.8M | 0.03% | 167 |
|
|
2023
Q3 | $50.2M | Sell |
1,637,076
-21,487
| -1% | -$774K | 0.05% | 146 |
|
|
2023
Q2 | $66.5M | Sell |
1,658,563
-232,278
| -12% | -$9.6M | 0.06% | 134 |
|
|
2023
Q1 | $77.2M | Buy |
1,890,841
+24,100
| +1% | +$959K | 0.07% | 128 |
|
|
2022
Q4 | $72.1M | Buy |
1,866,741
+18,944
| +1% | +$922K | 0.08% | 121 |
|
|
2022
Q3 | $98.3M | Sell |
1,847,797
-86,955
| -4% | -$4.84M | 0.1% | 119 |
|
|
2022
Q2 | $113M | Sell |
1,934,752
-184,848
| -9% | -$12.1M | 0.12% | 114 |
|
|
2022
Q1 | $162M | Sell |
2,119,600
-235,640
| -10% | -$15.7M | 0.11% | 109 |
|
|
2021
Q4 | $142M | Buy |
2,355,240
+267,433
| +13% | +$14.7M | 0.08% | 128 |
|
|
2021
Q3 | $117M | Sell |
2,087,807
-14,952
| -0.7% | -$862K | 0.06% | 138 |
|
|
2021
Q2 | $128M | Buy |
2,102,759
+7,278
| +0.3% | +$461K | 0.06% | 141 |
|
|
2021
Q1 | $147M | Buy |
2,095,481
+131,686
| +7% | +$9.41M | 0.08% | 133 |
|
|
2020
Q4 | $118M | Buy |
1,963,795
+204,806
| +12% | +$12M | 0.07% | 126 |
|
|
2020
Q3 | $106M | Buy |
1,758,989
+299,363
| +21% | +$17.4M | 0.07% | 119 |
|
|
2020
Q2 | $76.6M | Buy |
1,459,626
+47,734
| +3% | +$1.99M | 0.06% | 116 |
|
|
2020
Q1 | $47.3M | Buy |
1,411,892
+24,447
| +2% | +$1.02M | 0.05% | 114 |
|
|
2019
Q4 | $62.9M | Buy |
1,387,445
+235,735
| +20% | +$10M | 0.06% | 117 |
|
|
2019
Q3 | $43.8M | Buy |
1,151,710
+156,871
| +16% | +$6.26M | 0.05% | 125 |
|
|
2019
Q2 | $43.3M | Buy |
994,839
+3,931
| +0.4% | +$167K | 0.05% | 129 |
|
|
2019
Q1 | $37.7M | Buy |
990,908
+57,367
| +6% | +$2.24M | 0.04% | 133 |
|
|
2018
Q4 | $40.2M | Buy |
933,541
+131,532
| +16% | +$6.14M | 0.05% | 122 |
|
|
2018
Q3 | $39.4M | Buy |
802,009
+220,009
| +38% | +$9.51M | 0.04% | 127 |
|
|
2018
Q2 | $18.7M | Buy |
582,000
+71,903
| +14% | +$2.48M | 0.02% | 147 |
|
|
2018
Q1 | $15.9M | Buy |
510,097
+139,935
| +38% | +$4.98M | 0.02% | 151 |
|
|
2017
Q4 | $16.9M | Buy |
370,162
+49,580
| +15% | +$1.96M | 0.02% | 140 |
|
|
2017
Q3 | $12M | Buy |
320,582
+19,582
| +7% | +$788K | 0.02% | 151 |
|
|
2017
Q2 | $14.4M | Buy |
301,000
+87,400
| +41% | +$4.06M | 0.02% | 142 |
|
|
2017
Q1 | $9.74M | Hold |
213,600
| – | – | 0.01% | 153 |
|
|
2016
Q4 | $6.9M | Hold |
213,600
| – | – | 0.01% | 169 |
|
|
2016
Q3 | $7.31M | Hold |
213,600
| – | – | 0.01% | 167 |
|
|
2016
Q2 | $7.21M | Buy |
213,600
+186,100
| +677% | +$9.15M | 0.01% | 164 |
|
|
2016
Q1 | $1.46M | Buy |
27,500
+1,300
| +5% | +$76K | ﹤0.01% | 190 |
|
|
2015
Q4 | $2.01M | Hold |
26,200
| – | – | ﹤0.01% | 175 |
|
|
2015
Q3 | $1.08M | Buy |
+26,200
| New | +$1.6M | ﹤0.01% | 187 |
|
Other funds holding PCRX
DPCM
Baillie Gifford & Co's PCRX Position: Q3 2024 in Review
Baillie Gifford & Co sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 806,097 shares — an estimated $23.1M sold.
Baillie Gifford & Co first reported a position in PCRX in Q3 2015 and held it in 36 quarters. The position peaked at $162M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.
- Baillie Gifford & Co reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
- Baillie Gifford & Co sold 806,097 Pacira BioSciences shares in Q3 2024, an estimated $23.1M.
- Baillie Gifford & Co first reported a position in Pacira BioSciences in Q3 2015 and held it in 36 quarters.
- Baillie Gifford & Co's Pacira BioSciences position peaked at $162M in Q1 2022.
- 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.
Based on Baillie Gifford & Co's 13F filing for Q3 2024, filed 5 Nov 2024.